Stroke and Vascular Neurology | |
Is tenecteplase ready to replace alteplase to treat acute ischaemic stroke? The knowns and unknowns | |
article | |
Yi Dong1  Yi Sui2  Xin Cheng1  David Z Wang4  | |
[1] Department of Neurology , Huashan Hospital Fudan University;Department of Neurology, Shenyang Brain Hospital , Shenyang Medical College;Department of Neurology , The First People's Hospital of Shenyang;Department of Neurology , Barrow Neurological Institute | |
关键词: cerebral infarction; stroke; clinical trial; thrombolysis; thrombectomy; | |
DOI : 10.1136/svn-2021-001321 | |
学科分类:社会科学、人文和艺术(综合) | |
来源: BMJ Publishing Group | |
【 摘 要 】
Tenecteplase (TNKase, TNK-tPA or TNK)is a thrombolytic agent derived from thetissue plasminogen activator (tPA). It is a527-amino acid glycoprotein developed byreplacing three amino acids at the T, N andK positions of the glycoprotein structure oftPA under genetic recombinant technology.After replacing threonine 103 with asparagine, asparagine 117 with glutamine and atetra-alanine at amino acids 296–299, TNKis about eightfold more potent in dissolvingclot, 80-fold higher resistance to plasminogenactivator inhibitor-1 and 14-fold enhancedrelative fibrin specificity, and with a longerhalf-life (20min).1 Hence, TNK is administered as a single intravenous bolus.
【 授权许可】
CC BY-NC|CC BY|CC BY-NC-ND
【 预 览 】
Files | Size | Format | View |
---|---|---|---|
RO202306290002597ZK.pdf | 321KB | download |